We have tested the T helper cell (TH ) potential of asymptomatic, HIV seropositive (HIV+) patients, using an in vitro assay for IL-2 production. Peripheral blood leukocytes (PBL) from 74 HIV+ patients and 70 HIV-control donors were tested for TH function when stimulated with influenza A virus (FLU), tetanus toxoid (TET), HLA alloantigens (ALLO), or PHA. Of the HIV+ patients, four different response patterns were observed: (a) patients who responded to all four stimuli (16%); (b) patients who were selectively unresponsive to FLU and TET, but responded to ALLO and PHA (54%); (c) patients who were unresponsive to FLU, TET, or ALLO, but responsive to PHA (16%); and (d) patients who failed to respond to any of these stimuli (14%). Our results indicate a time-dependent progression from a stage responsive to all four stimuli to a stage unresponsive to any of the stimuli tested, progressing in the order outlined above.
Introduction
It is well established that the T lymphocyte-mediated immune defects in patients with AIDS are associated with a severe reduction in the number of CD4+ T lymphocytes (1) (2) (3) (4) (5) . Furthermore, it is considered that the loss of CD4+ T cells is the result of infection with HIV, although the mechanism(s) by which HIV depletes CD4+ T cells has not been determined. However, before a severe depletion of CD4' cells, a long period without apparent syndrome progression can ensue between the time of infection and development of AIDS symptoms (6) (7) (8) (9) (10) . This period is characterized by near normal numbers ofCD4' cells, absence of symptoms, positive delayed skin reactions, and positive in vitro proliferative responses to antigenic and mitogenic stimuli, and can be followed by a progressive and sometimes rapid deterioration resulting in symptomatic AIDS.
Early detection of HIV-induced, immune-related changes is important for identification and understanding of the initial events leading to HIV-associated immune dysregulation. Furthermore, detection of early changes in immune parameters would be useful for timing of therapeutic intervention as well as for monitoring immunologic changes that might result from therapy. Early indicators of progression toward AIDS include reduced numbers of CD4' cells, a decline ofantibodies specific for HIV viral proteins, and an appearance of viral antigens (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . In a previous study, we observed that PBL from some otherwise asymptomatic HIV seropositive (HIV+) individuals exhibited a defect in cytotoxic T lymphocyte (CTL)' responses to influenza A virus, but not to HLA alloantigens (1 1) . These results can be explained by a defect in CD41 T helper cell (TH) function, even though CD4' cell numbers were not critically reduced in these patients.
In the present report we have assessed TH function by using an in vitro assay for IL-2 production. PBL from Walter Reed Stage 1 (WR 1) and 2 (WR 2) patients were stimulated with influenza virus (FLU), tetanus toxoid (TET), alloantigens (ALLO), and PHA. This panel of stimuli was selected for study because (14) . The HIV-control donors were USAF personnel of the same sex and with the same age range as the HIV+ donors.
Lymphocyte counts and T cell subsets were determined using laser-based flow cytometry (Coulter Epics Profile; Coulter Electronics, Inc., Hialeah, FL) and OKT4A (anti-CD4) and OKT8 (anti-CD8) monoclonal antibodies (Orthodiagnostics Systems, Raritan, NJ).
Skin testing for recall antigens was performed using intradermal injections of0.02 ml ofPPD (5TU) (Connaught Laboratories, Ontario, Canada), Candida albicans ('/500) (Hollister-Stier, Spokane, WA), Tricophyton ('/500) ( 1 and WR 2 patients to respond to any combination ofthese stimuli did not appear to be correlated with CD4' cell numbers (see below).
Using the criteria described in Methods, we determined the number of individuals in the group of 74 patients and 70 controls who responded to FLU, TET, ALLO, or PHA by IL-2 production. We also tested 49 of these same patients and 58 of the controls for proliferative responses to the same stimuli. The numbers and percentages of patients and controls who were unresponsive to each of the stimuli by either of the two TH tests are presented in Table I . 62 of the 74 HIV+ donors (84%) failed to respond to FLU or TET by the IL-2 test. A much lower proportion of these donors was unresponsive to ALLO (30%), and an even lower proportion was unresponsive to PHA (14%). In contrast, only one HIV-control donor was unresponsive to FLU and TET, and none of the controls was unresponsive to ALLO or PHA. There was an exact concordance among individuals for both IL-2 and proliferative responses to FLU and TET. Again, similar to the IL-2 data, fewer patients failed to respond to ALLO than to FLU or TET, and even fewer did not respond to PHA. The percentage of HIV-controls that was unresponsive to FLU and TET was 1% as measured by IL-2 production and 3-5% by proliferation. All of the controls responded to ALLO Fig. 2 C with A, and H with 2F; P < 0.01 for FLU and P < 0.01 for TET), and also significantly below those of the responsive HIV+ patients (compare Fig. 2 Cwith B, and Hwith G; P < 0.05 for FLU and P < 0.05 for TET). IL-2 production did not differ significantly among these three groups for responses to ALLO and PHA (Fig. 2 , K-Mand P-R). The 12 patients who responded only to (Table III) . with time in a given patient. Fig. 3 illustrates a longitudinal comparison of FLU-stimulated IL-2 production by PBL from three donors who have been involved in this study for several years. PBL from the donor shown in Fig. 3 A were cryopreserved in 1983 and in 1988. This donor remained asymptomatic throughout the 4.5-yr period and had 573/mm3 of CD4' cells at the time of the last blood collection. PBL from the donor in Fig. 3 Fig. 3 A) or with FLU only (donors in Fig. 3 , B and C). These results (Fig. 3 response to FLU and TET in the donor in Fig. 3 A was not due to a critically low number ofCD4+ cells. Due to limitations on the number ofcryopreserved PBL available, it was not possible to test these individuals for TH function to ALLO or PHA. It should also be noted that PBL from HIV-donors frozen in 1983 and tested in 1988 still retained a strong TH function to FLU and TET (data not shown).
To obtain a more precise time estimate for development of TH unresponsiveness, an asymptomatic, HIV+ donor was studied at 4-mo intervals to detect possible loss ofTH function. Fig.  4 illustrates the titration curves for IL-2 production by PBL stimulated with FLU, TET, ALLO, or PHA. In March 1988, the patient was marginally responsive to FLU and TET, but was strongly responsive to ALLO (Fig. 4 A) . (PHA was not tested in this experiment.) During the next 8 mo, the patient's FLU and TET responses continued to decline to unstimulated levels, whereas the ALLO and PHA responses remained strong (Fig. 4, B and C) . During this time interval, the patient did not develop any symptoms and CD4+ and CD8+ T cell numbers increased slightly. In all three experiments, PBL from HIVcontrol donors generated potent TH responses to all four stimuli (data not shown). These data demonstrate that loss of TH function to recall antigens can occur abruptly and is not neces-sarily associated with symptomatic changes nor with a reduction in CD4' cell numbers.
To further investigate possible progression in TH defects, we have studied IL-2 responses of PBL from patients in the more advanced WR 3 to WR 6. If the failure to produce IL-2 in response to ALLO represents TH dysfunction associated with more advanced stages of AIDS progression, then a larger proportion of WR 3 to WR 6 patients should be unresponsive to FLU or TET, and also to ALLO. The proportions of IL-2 responses by 22 patients are summarized in Table IV and are compared with the proportions of responses by our 74 WR 1 and WR 2 patients using the same two stimuli. The majority of the WR 3 to WR 6 failed to respond to FLU or ALLO (64%) compared with only 30% of the WR 1 and WR 2 patients who failed to respond to both stimuli. The statistical likelihood that these frequency differences between WR 1 and WR 2 and WR 3 to WR 6 patients were due to chance was < 1%. Thus, these results support the hypothesis that the TH functional phases shown in Figs. 1 and 2 represent a sequential progression of immune dysfunction that is associated with progression toward AIDS.
Discussion
Other studies have reported that the T cell responses to recall antigens may be defective in some HIV+ patients who do not have AIDS (17-20). Our laboratory ( 11) has previously demonstrated a selective defect in CTL responses to FLU but not to ALLO in asymptomatic, HIV+ individuals. Because the deficient CTL response to FLU could be corrected in vitro by recombinant IL-2, the CTL defect appeared to reflect an underlying deficiency in CD4' TH function. A similar IL-2-correctable defect in CTL function has been reported in patients with symptomatic AIDS (21). These findings indicate that: (a) IL-2 is a helper lymphokine for human CTL generation; and (b) this lymphokine is deficient in HIV-infected individuals. The present study measures TH function directly by assessing IL-2 production and extends these findings by: (a) identifying a series of three distinct TH functional defects in asymptomatic patients; (b) demonstrating a time-dependent progressive and selective loss of TH function in individual asymptomatic patients; and (c) attempting to correlate these defects with clinical staging criteria.
The three different patterns of TH dysfunction identified among these asymptomatic patients were (a) a selective loss of TH function to recall antigens such as FLU and TET, but retention of TH function upon stimulation to ALLO or PHA (54%); (b) an absence of TH function to the recall antigens and to ALLO, but preserved responses to PHA (16%); and (c) a (12) . Therefore, the selective defect in TH responses to FLU and TET in 84% of our patients can be attributed to an early immune dysfunction that selectively affects CD4' TH and/or autologous APC. CD8' T cells would be unaffected and could respond to ALLO and PHA.
The loss in TH function in asymptomatic patients is not due to a critical reduction in CD4' cell numbers and, therefore, must be attributed to some other mechanism(s). CD4' cells could be infected without being killed and such infected cells would be nonfunctional (22) . However, this possibility appears to be unlikely because in situ hybridization studies indicate that the frequency of infected leukocytes is less than 1/103 (23) . An alternative possible mechanism is suggested by the recent report that the sera of some AIDS patients (24) , as well as some asymptomatic HIV+ individuals (25) 30) , and because this early defect is limited to antigens that require CD4' TH cells and autologous APC, it is possible that antigen-presenting function rather than TH function is defective in these patients. However, preliminary studies from our laboratory comparing the TH and APC functions of cells from individual, asymptomatic patients, before and after the loss of TH response to FLU and TET, have not shown any defect in APC function (manuscript in preparation). Thus, the mechanism(s) responsible for the early TH dysfunction in asymptomatic, HIV+ individuals remains unresolved, but is under investigation.
We have defined responsive and unresponsive patients by the statistical method described in Methods. Stimulation indices of 2.0 or greater have also been used to define responsiveness in other studies (31) . We compared both methods in the present study, and found no differences in the percentage of unresponsive donors for the [3H]thymidine assay by either approach. Thus, 80% of the WR 1 and WR 2 patients were unresponsive to FLU and TET, irrespective of which method was used. However, we did find that a lower percentage (57%) of patients were unresponsive to FLU and TET if we used a stimulation index of 2.0 rather than 3 SD above the mean background method (84%). Regardless of which method is used and whether TH function is measured by IL-2 production or by [3H]thymidine incorporation, a majority of WR 1 and WR 2 patients are unresponsive to recall antigens.
Despite our finding that the WR 1 and WR 2 patients exhibit CD4' TH defects, they do not have opportunistic infections. It is possible that the loss of CD4' TH function is responsible for a nonprogressive period after HIV infection. For example, the observation that CD4' T cells must be activated for HIV to be infectious (32, 33) 
